Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ceftaroline Fosamil→

Ceftaroline Fosamil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
229016-73-3
Molecular formula
C22H21N8O8PS4
Molecular weight
684.7 g/mol
Drug class
Fifth-generation cephalosporin prodrugbeta-lactam antibacterial
Mechanism of action
Ceftaroline fosamil is converted by phosphatases to active ceftaroline. Ceftaroline binds penicillin-binding proteins, including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), and inhibits bacterial cell-wall synthesis.
Indications / reported uses
  • Treatment of acute bacterial skin and skin-structure infections, including those caused by susceptible MRSA
  • Treatment of community-acquired bacterial pneumonia caused by susceptible pathogens; exact age and organism criteria are product-label specific

Sources: US DailyMed — TEFLARO (ceftaroline fosamil) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ceftaroline Fosamil Environmental Risk Assessment (ERA) (the Ceftaroline Fosamil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.